Occam Global has placed Ali Fattaey, Phd as the Chief Executive Officer of Metabomed, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism. Investors include M Ventures, Pfizer Ventures, Pontifax Venture Fund, Boehringer Ingelheim Venture Fund and Arkin Bio Ventures.
Dr. Fattaey brings over 20 years of experience in private and public biotech executive management roles focused on cancer drug discovery and development. Most recently he served as President and Chief Executive Officer of Curis, Inc., a Boston-based biotechnology company dedicated to development of innovative medicines for patients with cancer. Dr. Fattaey has successfully raised significant capital in the private venture and public markets, recruited and built cancer drug development teams, and has established strategic partnerships and collaborations within the industry.